Immuneering Corporation
NASDAQ:IMRXBiotechnology
-$0.01 today
- Market cap
- $226.67M
- Beta
- 0.38
- P/E (TTM)
- -3.6
- EPS (TTM)
- -$1.24
Volume 0.73M
Average 1.38M
IMRX Cash & Equivalents
Cash on hand and highly liquid investments that can be converted to cash almost immediately.
Immuneering CorporationNASDAQ: IMRX
Cash & Equivalents · Q1 FY2026 · quarter ended Mar 2026
Cash & equivalents rises 31.9% from a year ago
Cash & equivalents stood at $47.32M at the end of Q1 FY2026, up 31.9% from a year earlier and down 63.2% from the prior quarter. Over 3 fiscal years it compounded at +21.0% a year.
Context
- Cash & equivalents amounted to 0.0% of total assets at the end of Q1 FY2026, down 70.7 pp from a year earlier.
- Cash & equivalents increased in 1 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether cash & equivalents keeps rising in the next quarterly balance sheet after a +31.9% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Cash & Equivalents history
USD · from the balance sheet
- Latest · FY2025
- 128.65M USD
- Year-over-year change
- +255.9%
- 4-year CAGR
- +14.5%
| Period | Period end | Cash & Equivalents | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 128.65M | +255.9% |
| FY2024 | 2024-12-31 | 36.14M | -39.2% |
| FY2023 | 2023-12-31 | 59.41M | -18.2% |
| FY2022 | 2022-12-31 | 72.64M | -3.0% |
| FY2021 | 2021-12-31 | 74.89M | — |
Cash & Equivalents vs competitors
How IMRX compares with its peers on the latest reported figures
- IMRX's Mar 2026 cash & equivalents of $47.32M is the 7th highest of the 11 companies compared; the peer median is $62.49M.
- Its year-over-year change of +31.9% is the 5th highest of 11, against a peer median of +5.1%.
- Cash & equivalents amounts to 0.0% of total assets for IMRX, versus a peer median of 31.4%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
ZURAZura Bio Limited | Mar 2026 | $225.59M | +32.3% | +311.8% | 98.7% |
| Mar 2026 | $211.38M | -2.6% | -16.2% | 86.1% | |
| Mar 2026 | $88.91M | +45.7% | +15.7% | 40.0% | |
| Mar 2026 | $80.89M | +50.4% | +1.8% | 59.9% | |
| Mar 2026 | $76.44M | +12.7% | +26.0% | 22.8% | |
| Mar 2026 | $48.54M | -22.8% | -30.4% | 43.9% | |
| Mar 2026 | $47.32M | +31.9% | +21.0% | 0.0% | |
| Mar 2026 | $34.93M | -42.0% | -9.8% | 11.1% | |
| Mar 2026 | $31.12M | +32.9% | +3.7% | 13.2% | |
| Mar 2026 | $14.63M | -56.0% | -52.4% | 8.2% | |
| Mar 2026 | $7.24M | -43.3% | -55.9% | 11.3% | |
| Peer median (excluding IMRX) | $62.49M | +5.1% | -4.0% | 31.4% | |
Competitors are the stored peer set for IMRX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 74.89M | 72.64M | 59.41M | 36.14M | 128.65M |
| Short-term Investments | 74.31M | 32.89M | 26.26M | 0 | 44.19M |
| Net Receivables | 246.04K | 12.42K | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Other Current Assets | 0 | 3.21M | 3.42M | 3.44M | 3.41M |
| Total Current Assets | 152.33M | 108.75M | 89.08M | 39.59M | 176.25M |
| Property, Plant & Equipment (Net) | 6.13M | 5.78M | 5.4M | 4.79M | 4.26M |
| Goodwill | 6.7M | 6.69M | 6.69M | 6.69M | 6.69M |
| Intangible Assets | 439K | 408.95K | 379.68K | 350.41K | 321.15K |
| Long-term Investments | 996.56K | 0 | 0 | 0 | 0 |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 102.13K | 743.7K | 1.03M | 1.3M | 44.47M |
| Total Non-current Assets | 14.37M | 13.62M | 13.5M | 13.13M | 55.74M |
| Total Assets | 166.7M | 122.37M | 102.58M | 52.71M | 231.99M |
| Account Payables | 1.39M | 3.15M | 2.11M | 1.96M | 1.54M |
| Short-term Debt | 0 | 0 | 0 | 0 | 0 |
| Tax Payables | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 2.92M | 3.65M | 3.89M | 3.82M | 4.54M |
| Total Current Liabilities | 5.63M | 8.05M | 7.85M | 7.5M | 10.07M |
| Long-term Debt | 0 | 0 | 0 | 0 | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 0 | 0 | 0 | 0 | 0 |
| Total Non-current Liabilities | 5.09M | 4.46M | 4.16M | 3.82M | 3.43M |
| Total Liabilities | 10.72M | 12.52M | 12.01M | 11.33M | 13.5M |
| Common Stock | 26.32K | 26.42K | 29.27K | 31.05K | 64.65K |
| Retained Earnings | (59.27M) | (109.79M) | (163.26M) | (224.3M) | (280.32M) |
| Accumulated OCI | (49.01K) | (30.12K) | (778) | 0 | 81.33K |
| Other Stockholders Equity | 0 | 0 | 0 | 1 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 155.98M | 109.85M | 90.58M | 41.39M | 218.48M |
| Total Debt | 5.36M | 4.84M | 4.46M | 4.16M | 3.82M |
| Net Debt | (69.52M) | (67.8M) | (54.94M) | (31.98M) | (124.82M) |
Immuneering Corporation
NASDAQ:IMRX
Intrinsic Alpha fair value
Locked
Current Price
$3.50
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.